AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Mass spectrometry (MS)-based proteomics and phosphoproteomics are powerful methods to study the biological mechanisms, diagnostic biomarkers, prognostic analysis, and drug therapy of tumors. Data-independent acquisition (DIA) mode is considered to perform better than data-dependent acquisition (DDA) mode in terms of quantitative reproducibility, specificity, accuracy, and identification of low-abundance proteins. Mini patient derived xenograft (MiniPDX) model is an effective model to assess the response to antineoplastic drugs in vivo and is helpful for the precise treatment of cancer patients. Kinases are favorable spots for tumor-targeted drugs, and their functional completion relies on signaling pathways through phosphorylating downstream substrates. Kinase-phosphorylation networks or edge interactions are considered more credible and permanent for characterizing complex diseases. Here, we provide a workflow for personalized drug response assessment in primary and metastatic colorectal cancer (CRC) tumors using DIA proteomic data, DIA phosphoproteomic data, and MiniPDX models. Three kinase inhibitors, afatinib, gefitinib, and regorafenib, are tested pharmacologically. The process mainly includes the following steps: clinical tissue collection, sample preparation, hybrid spectral libraries establishment, MS data acquisition, kinase-substrate network construction, in vivo drug test, and elastic regression modeling. Our protocol gives a more direct data basis for individual drug responses, and will improve the selection of treatment strategies for patients without the druggable mutation.
Aebersold R, Mann M (2016) Mass-spectrometric exploration of proteome structure and function. Nature 537(7620): 347−355
Bader JM, Geyer PE, Muller JB, Strauss MT, Koch M, Leypoldt F, Koertvelyessy P, Bittner D, Schipke CG, Incesoy EI, Peters O, Deigendesch N, Simons M, Jensen MK, Zetterberg H, Mann M (2020) Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Mol Syst Biol 16(6): e9356. https://doi.org/10.15252/msb.20199356
Barkovits K, Pacharra S, Pfeiffer K, Steinbach S, Eisenacher M, Marcus K, Uszkoreit J (2020) Reproducibility, specificity and accuracy of relative quantification using spectral library-based data-independent acquisition. Mol Cell Proteomics 19(1): 181−197
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L (2011) A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1(6): 508−523
Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, Purandare DM, Hattersley G, Garner F (2017) Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models. Clin Cancer Res 23(16): 4793−4804
Bilbao A, Varesio E, Luban J, Strambio-De-Castillia C, Hopfgartner G, Muller M, Lisacek F (2015) Processing strategies and software solutions for data-independent acquisition in mass spectrometry. Proteomics 15(5-6): 964−980
Bruderer R, Bernhardt OM, Gandhi T, Miladinovic SM, Cheng LY, Messner S, Ehrenberger T, Zanotelli V, Butscheid Y, Escher C, Vitek O, Rinner O, Reiter L (2015) Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. Mol Cell Proteomics 14(5): 1400−1410
Chen Y, Choong LY, Lin Q, Philp R, Wong CH, Ang BK, Tan YL, Loh MC, Hew CL, Shah N, Druker BJ, Chong PK, Lim YP (2007) Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics 6(12): 2072−2087
Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M (2020) DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods 17(1): 41−44
Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J, MacCoss MJ, Rinner O (2012) Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 12(8): 1111−1121
Gao E, Li W, Wu C, Shao W, Di Y, Liu Y (2021) Data-independent acquisition-based proteome and phosphoproteome profiling across six melanoma cell lines reveals determinants of proteotypes. Mol Omics 17(3): 413−425
Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E, 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Roelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 21(11): 1318−1325
Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J (2019) Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 179(2): 561−577
Gilar M, Olivova P, Daly AE, Gebler JC (2005) Two-dimensional separation of peptides using RP-RP-HPLC system with different pH in first and second separation dimensions. J Sep Sci 28(14): 1694−1703
Gotti C, Roux-Dalvai F, Joly-Beauparlant C, Mangnier L, Leclercq M, Droit A (2021) Extensive and accurate benchmarking of DIA acquisition methods and software tools using a complex proteomic standard. J Proteome Res 20(10): 4801−4814
Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 70(22): 9391−9401
Ihaka R, Gentleman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5(3): 299−314
Kitata RB, Choong WK, Tsai CF, Lin PY, Chen BS, Chang YC, Nesvizhskii AI, Sung TY, Chen YJ (2021) A data-independent acquisition-based global phosphoproteomics system enables deep profiling. Nat Commun 12(1): 2539. https://doi.org/10.1038/s41467-021-22759-z
Krasny L, Huang PH (2021) Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Mol Omics 17(1): 29−42
Li C, Sun YD, Yu GY, Cui JR, Lou Z, Zhang H, Huang Y, Bai CG, Deng LL, Liu P, Zheng K, Wang YH, Wang QQ, Li QR, Wu QQ, Liu Q, Shyr Y, Li YX, Chen LN, Wu JR, Zhang W, Zeng R (2020) Integrated omics of metastatic colorectal cancer. Cancer Cell 38(5): 734−747
Lou R, Tang P, Ding K, Li S, Tian C, Li Y, Zhao S, Zhang Y, Shui W (2020) Hybrid spectral library combining DIA-MS data and a targeted virtual library substantially deepens the proteome coverage. iScience 23(3): 100903. https://doi.org/10.1016/j.isci.2020.100903
Ludwig C, Gillet L, Rosenberger G, Amon S, Collins BC, Aebersold R (2018) Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial. Mol Syst Biol 14(8): e8126. https://doi.org/10.15252/msb.20178126
Manley PW, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W, Strauss A, Wood J (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 1697(1-2): 17−27
Meier-Abt F, Lu J, Cannizzaro E, Pohly MF, Kummer S, Pfammatter S, Kunz L, Collins BC, Nadeu F, Lee KS, Xue P, Gwerder M, Roiss M, Hullein J, Scheinost S, Dietrich S, Campo E, Huber W, Aebersold R, Zenz T (2021) The protein landscape of chronic lymphocytic leukemia (CLL). Blood 138(24): 2514−2525
Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2(8): 1896−1906
Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R (2014) Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res 74(23): 6980−6990
Rosenberger G, Koh CC, Guo T, Röst HL, Kouvonen P, Collins BC, Heusel M, Liu Y, Caron E, Vichalkovski A, Faini M, Schubert OT, Faridi P, Ebhardt HA, Matondo M, Lam H, Bader SL, Campbell DS, Deutsch EW, Moritz RL, Tate S, Aebersold R (2014) A repository of assays to quantify 10, 000 human proteins by SWATH-MS. Sci Data 1(1): 140031. https://doi.org/10.1038/sdata.2014.31
Sajic T, Liu Y, Aebersold R (2015) Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin Appl 9(3-4): 307−321
Schubert OT, Gillet LC, Collins BC, Navarro P, Rosenberger G, Wolski WE, Lam H, Amodei D, Mallick P, MacLean B, Aebersold R (2015) Building high-quality assay libraries for targeted analysis of SWATH MS data. Nat Protoc 10(3): 426−441
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11): 2498−2504
Song C, Ye M, Han G, Jiang X, Wang F, Yu Z, Chen R, Zou H (2010) Reversed-phase-reversed-phase liquid chromatography approach with high orthogonality for multidimensional separation of phosphopeptides. Anal Chem 82(1): 53−56
Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P (2009) Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 15(20): 6327−6340
Sun Y, Li C, Pang S, Yao Q, Chen L, Li Y, Zeng R (2020) Kinase-substrate edge biomarkers provide a more accurate prognostic prediction in ER-negative breast cancer. Genomics Proteomics Bioinformatics 18(5): 525−538
Surmen MG, Surmen S, Ali A, Musharraf SG, Emekli N (2020) Phosphoproteomic strategies in cancer research: a minireview. Analyst 145(22): 7125−7149
Tsou CC, Tsai CF, Teo GC, Chen YJ, Nesvizhskii AI (2016) Untargeted, spectral library-free analysis of data-independent acquisition proteomics data generated using Orbitrap mass spectrometers. Proteomics 16(15-16): 2257−2271
Tyanova S, Temu T, Cox J (2016) The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc 11(12): 2301−2319
Wang X, Sun Y, Xu Y, Wen D, An N, Leng X, Fu G, Lu S, Chen Z (2021) Mini-patient-derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non-small cell lung cancer. Cell Biol Int 45(9): 1887−1896
Weitsman G, Lawler K, Kelleher Muireann T, Barrett JE, Barber Paul R, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis Iain DC, Woodman N, Ofo E, Ameer-Beg Simon M, Irshad S, Condeelis J, Gillett Cheryl E, Ellis Paul A, Vojnovic B, Coolen Anthony CC, Ng T (2014) Imaging tumour heterogeneity of the consequences of a PKCα–substrate interaction in breast cancer patients. Biochem Soc Trans 42(6): 1498−1505
Willems P, Fels U, Staes A, Gevaert K, Van Damme P (2021) Use of hybrid data-dependent and -independent acquisition spectral libraries empowers dual-proteome profiling. J Proteome Res 20(2): 1165−1177
Wiredja DD, Koyuturk M, Chance MR (2017) The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics. Bioinformatics 33(21): 3489−3491
Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5): 359−362
Zhan M, Yang RM, Wang H, He M, Chen W, Xu SW, Yang LH, Liu Q, Long MM, Wang J (2018) Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun (Lond) 38(1): 48. https://doi.org/10.1186/s40880-018-0318-8
Zhang F, Wang W, Long Y, Liu H, Cheng J, Guo L, Li R, Meng C, Yu S, Zhao Q, Lu S, Wang L, Wang H, Wen D (2018) Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun (Lond) 38(1): 60. https://doi.org/10.1186/s40880-018-0329-5
Zhang Y, Bilbao A, Bruderer T, Luban J, Strambio-De-Castillia C, Lisacek F, Hopfgartner G, Varesio E (2015) The use of variable Q1 isolation windows improves selectivity in LC-SWATH-MS acquisition. J Proteome Res 14(10): 4359−4371
Zhao P, Chen H, Wen D, Mou S, Zhang F, Zheng S (2018) Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. Cancer Commun (Lond) 38(1): 54. https://doi.org/10.1186/s40880-018-0323-y
Zou H, Hastie T (2005) Regularization and variable selection via the elastic net. J R Statist Soc B 67(2): 301−320
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
